The Age-Dependent Increase of Metabolic Syndrome Requires More Extensive and Aggressive Non-Pharmacological and Pharmacological Interventions: A Cross-Sectional Study in an Italian Cohort of Obese Women

Table 5

Obese patients with or without metabolic syndrome, subdivided among age ranges, treated with hypolipidaemic drugs, hypoglycaemics, and/or antihypertensives and successfully controlled in accordance with the cut-offs of the IDF diagnostic criteria for HDL-C, triglycerides, glucose, and blood pressure.

Successfully controlled
IDF parameter	18–30	31–40	41–50	51–60	61–70	>70	β1	Y-intercept
HDL-C (≥50 mg/dl)
MetS+	1/2 (50.0%)	1/9 (11.1%)	4/9 (44.4%)	14/45 (31.1%)	20/41 (48.8%)	4/11 (36.4%)	0.005	0.85	0.247
MetS-	—	—	—	—	—	—	—	—	—
Triglycerides (<150 mg/dl)
MetS+	1/2 (50.0%)	5/9 (55.5%)	3/9 (33.3%)	17/45 (37.8%)	26/41 (63.4%)	8/11 (72.7%)	0.009	-0.022	0.038
MetS-	—	—	—	—	—	—	—	—	—
Glucose (<100 mg/dl)
MetS+	2/3 (66.7%)	5/12 (41.6%)	4/26 (15.4%)	18/78 (23.1%)	15/60 (25.0%)	2/20 (10.0%)	−0.005	0.53	0.067
MetS-	—	—	—	1/1 (100.0%)	0/1 (0.0%)	—	—	—	—
Blood pressure (SBP <130 and/or DBP <85)
MetS+	2/7 (28.6%)	12/26 (46.1%)	41/79 (51.9%)	73/159 (45.9%)	66/155 (42.6%)	21/43 (48.8%)	−0.001	0.53	0.551
MetS-	0/1 (0.0%)	2/6 (33.3%)	11/22 (50.0%)	21/47 (44.7%)	8/28 (28.6%)	6/14 (42.8%)	−0.003	0.61	0.425

Values are expressed in percent (% to the number of patients within the corresponding age range). Abbreviations: MetS-, negative for metabolic syndrome; MetS+, positive for metabolic syndrome. a: versus the corresponding MetS- subgroup (Fisher's exact test). Values of β1, Y-intercept, and refer to the linear regression performed by using all data within each subgroup (MetS + or MetS-). The symbol “-” means non-determinable or no-napplicable.